🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Brief Strategic Family Therapy (BSFT)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  2. Budesonide

    Bausch + Lomb Ireland Limited

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  3. Bupivacaine

    United Therapeutics Europe Ltd

    Postoperative Pain

    phase 3 small molecule active

    1 trial

  4. Bupivacaine HCl

    Pacira Ireland Limited

    Postoperative Pain

    phase 3 small molecule completed

    3 trials

  5. Bupivacaine Liposome Injection

    United Therapeutics Europe Ltd

    Osteoarthritis

    phase 3 small molecule terminated

    1 trial

  6. C1 esterase inhibitor [human] (C1INH-nf)

    Takeda

    Hereditary Angioedema

    phase 3 mab completed

    5 trials

  7. C1 esterase inhibitor [human] liquid

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  8. CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    AstraZeneca AB

    Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  9. CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

  10. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  11. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  12. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial

  13. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Psychosis

    phase 3 small molecule active

    1 trial

  14. CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME

    Pari Pharma GmbH

    antibiotic therapy in Sepsis

    phase 3 small molecule active

    1 trial

  15. CF101

    Can-Fite BioPharma

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    2 trials

  16. CISPLATIN, FLUOROURACIL, MITOMYCIN, CAPECITABINE, CAPECITABINE, DOCETAXEL

    CERO THERAPEUTICS HOLDINGS, INC.

    locally advanced anal squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  17. CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS, Placebo to Clostridium Botulinum neurotoxin type A (150 kD)

    Merz Therapeutics GmbH

    Episodic migraine

    phase 3 small molecule active

    1 trial

  18. CMF regimen

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    2 trials

  19. COMP360 psilocybin

    Compass Therapeutics

    PTSD - Post Traumatic Stress Disorder

    phase 3 small molecule active

    1 trial

  20. CONDROSULF 800 mg tabletta

    The George Institute

    Knee osteoarthritis with moderate to severe pain

    phase 3 small molecule active

    1 trial

  21. CP101

    Finch Therapeutics Group

    Recurrent C. Difficile Infection

    phase 3 mab terminated

    1 trial

  22. CPI-0610, CPI-0610

    Novartis Pharmaceuticals

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  23. CSII (Insulin Pump) plus DAFNE

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 3 other completed

    1 trial

  24. CTX-009

    Compass Therapeutics

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources